Navigation Links
Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
Date:2/3/2009

10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contact:
    Investors                                     Media
    Eugenia Shen                                  Susan Berg
    BioMarin Pharmaceutical Inc.                  BioMarin Pharmaceutical Inc.
    (415) 506-6570                                (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
2. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
3. Corgenix to Host Conference Call to Discuss Second Quarter Results
4. BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results
5. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
6. Cardica Announces Fiscal 2009 Second Quarter Financial Results
7. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
9. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
10. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
11. Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... , Aug. 19, 2014 A Geisinger researcher ... nominated for a Centers for Disease Control and Prevention ... major public health concern. Joseph Boscarino ... one of a team of researchers nominated for the ... Shepard Science Award for Data Methods and Study Design. ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership ... production from bioactive small molecules. Based on ... enables convenient and timely assessment of critical metabolite ... President of Commercial Operations, Christian Darabant, “the value ... can be measured directly by comparison with the ...
(Date:8/19/2014)... ROCKVILLE, Md. , Aug. 19, 2014 /PRNewswire/ ... a biotechnology company developing novel anti-infective biologic and ... infections and diseases, announced today that its novel ... highlighted at the 54 th Interscience Conference ... in Washington D.C. ...
Breaking Biology Technology:Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... 27 The Infectious Disease Research,Institute (IDRI), a Seattle-based ... Davis has joined its team as Interim CEO, to,assist ... biotech innovator in global health., "Steve will be ... and Head of Research & Development. "He can help ...
... Schering-Plough,Corporation (NYSE: SGP ) today ... vice president, investor relations, effective immediately., ... for developing, implementing,and continually improving a comprehensive ... lead the formulation and execution of,external and ...
... Product Launch Planned for September 2008, PLYMOUTH MEETING, ... BJGP ) (,BMP Sunstone, or the ,Company,),today announced that ... the,SFDA to market a new Propess applicator in China., ... for cervix dilation to,help induce labor, and is currently ...
Cached Biology Technology:Steve Davis Joins Infectious Disease Research Institute (IDRI) as Interim CEO 2Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations 2BMP Sunstone Receives Import Drug License (IDL) from SFDA 2BMP Sunstone Receives Import Drug License (IDL) from SFDA 3
(Date:8/20/2014)... Ore. -- When are athletes who have suffered concussions ... Oregon study has found that high school athletes who ... 60 days experience a significant regression in their abilities ... The regression, as seen in changes in their balance ... 19 athletes. Ten of the 12 had returned to ...
(Date:8/20/2014)... the past few years, Virginia Tech,s Wu Feng has ... grant from the "Computing in the Cloud" program, and ... $6 million award from the Air Force on "big ... NSF and the National Institutes of Health on "big ... together the "parallel computing" aspects from each grant, he ...
(Date:8/20/2014)... A new gene therapy developed by researchers at ... shown to protect mice from a life-threatening heart condition ... new therapeutic avenue," said Yi Lai, Ph.D., the leading ... the MU School of Medicine,s Department of Molecular Microbiology ... we hope this could lead to a treatment for ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Gene therapy protects mice from lethal heart condition, MU researchers find 2
... was so rude and condescending? Or why the mid-level manager ... Or, on a more profound level, why the guards at ... a new study, researchers at USC, Stanford and the Kellogg ... possess power but lack status have a tendency to engage ...
... DigitalPersona, Inc. , a global provider of authentication and ... owned by the chain,s franchisees are improving their loss ... such KFC franchisees, West Quality Food Service, Inc. ... U.are.U® Fingerprint Readers, which are now available through the ...
... extended statewide dry spell, researchers at the Texas AgriLife ... been focusing their attention on improving varieties of more ... "We,re looking into improved varieties of melons, such as ... Spanish and Italian specialty melons that are relatively new ...
Cached Biology News:Power corrupts, especially when it lacks status 2Power corrupts, especially when it lacks status 3KFC Restaurants Across the U.S. Serve Up Loss Prevention With DigitalPersona Fingerprint Biometrics 2KFC Restaurants Across the U.S. Serve Up Loss Prevention With DigitalPersona Fingerprint Biometrics 3Texas AgriLife Research scientists making better melons 2Texas AgriLife Research scientists making better melons 3Texas AgriLife Research scientists making better melons 4